5-FLUOROURACIL "EBEWE" 500mg/10ml Infusion/Concentrate for

What is 5-FLUOROURACIL "EBEWE" 500mg/10ml

5-FLUOROURACIL "EBEWE" 500mg/10ml is a chemotherapeutic medication used extensively in oncology for the treatment of various types of cancers. It is supplied as a concentrated infusion solution in a 10ml glass vial and contains fluorouracil as the active ingredient. Fluorouracil is classified as an antimetabolite, which interferes with the synthesis of DNA and RNA, essential components for cancer cell proliferation.

• Commonly used in the treatment of colorectal, breast, head and neck, gastric, and pancreatic cancers.
• Available as an intravenous infusion or bolus injection after dilution, typically administered by specialized oncology healthcare providers.
• Acts selectively on rapidly dividing malignant cells, reducing tumor growth and spread.
• Often incorporated into combination chemotherapy regimens to improve treatment efficacy.
• Requires close monitoring due to its potential toxicity and narrow therapeutic index.

5-FLUOROURACIL "EBEWE" is a cornerstone drug in cancer chemotherapy, essential in both curative and palliative cancer management.

How to use 5-FLUOROURACIL "EBEWE" 500mg/10ml

The administration of 5-FLUOROURACIL "EBEWE" requires careful preparation and monitoring:

• Preparation: The concentrate must be diluted appropriately with compatible infusion fluids such as 0.9% sodium chloride or 5% dextrose before administration.
• Route: Administered intravenously, either as a slow bolus injection or continuous infusion, depending on the treatment protocol.
• Dosage and Schedule: Determined by the oncologist based on the type of cancer, patient’s weight or body surface area, and treatment goals.
• Monitoring: Frequent blood tests including complete blood count (CBC), liver and kidney function tests to detect toxicity and adjust dosage.
• Handling Precautions: Healthcare workers should use protective gloves and follow cytotoxic drug handling guidelines to avoid accidental exposure.
• Patient Care: Patients should be educated on the importance of reporting side effects promptly and adhering strictly to scheduled follow-ups.

Because of the drug’s toxicity and complexity, 5-FLUOROURACIL "EBEWE" should only be used under strict medical supervision in specialized oncology centers.

Mode of Action 5-FLUOROURACIL "EBEWE" 500mg/10ml

5-FLUOROURACIL (5-FU) acts primarily by disrupting nucleic acid metabolism in cancer cells:

• Conversion to Active Metabolites: Inside the cell, 5-FU is metabolized into fluorodeoxyuridine monophosphate (FdUMP) and fluorouridine triphosphate (FUTP).
• Inhibition of Thymidylate Synthase: FdUMP binds to and inhibits thymidylate synthase, an enzyme critical for synthesizing thymidine nucleotides necessary for DNA replication.
• RNA Incorporation: FUTP integrates into RNA molecules, disrupting normal RNA processing and protein synthesis.
• Selective Targeting: Cancer cells, due to their rapid division, are more susceptible to these disruptions, leading to apoptosis (programmed cell death).
• Synergistic Effects: Often administered with leucovorin, which enhances the binding of FdUMP to thymidylate synthase, boosting the drug’s efficacy.

This dual mechanism results in effective inhibition of tumor growth by impairing DNA and RNA functions.

5-FLUOROURACIL "EBEWE" 500mg/10ml Interactions 5-FLUOROURACIL "EBEWE" 500mg/10ml

Several drug interactions may influence the safety and effectiveness of 5-FLUOROURACIL:

• Leucovorin (Folinic Acid): Potentiates the effects of 5-FU by stabilizing the enzyme-drug complex, increasing cytotoxicity.
• Warfarin: Increased anticoagulant effect has been observed, raising bleeding risk; requires close INR monitoring.
• Phenytoin: 5-FU can increase phenytoin levels leading to toxicity; serum levels should be monitored.
• Cytotoxic Drugs: Combined chemotherapy regimens may amplify toxicity and require dose adjustments.
• Radiation Therapy: Concurrent use may enhance side effects like mucositis and skin toxicity.
• DPD Inhibitors: Drugs inhibiting dihydropyrimidine dehydrogenase (the enzyme that metabolizes 5-FU) can lead to increased 5-FU toxicity.

Always inform your healthcare team about all medications being taken to prevent adverse interactions.

Dosage of 5-FLUOROURACIL "EBEWE" 500mg/10ml

The dosage of 5-FLUOROURACIL depends on multiple clinical factors:

• Typical Dose Range: Often dosed at 300-600 mg/m²/day, administered via bolus injection or continuous infusion based on treatment protocols.
• Cancer Type and Stage: Specific dosing schedules are tailored to cancer type, such as colorectal, breast, or head and neck cancer.
• Combination Therapy: Dose adjustments may be necessary when combined with agents like leucovorin, cisplatin, or other chemotherapeutics.
• Patient Factors: Adjustments for age, renal and hepatic function, and bone marrow reserve are critical to minimize toxicity.
• Cycle Scheduling: Typically administered in cycles (e.g., every 2-4 weeks) with rest periods for recovery of healthy tissues.
• Monitoring: Dosage must be frequently reviewed based on clinical response and adverse effects.

Only oncology specialists should determine and modify the dosing regimen for each individual patient.

Possible side effects of 5-FLUOROURACIL "EBEWE" 500mg/10ml

5-FLUOROURACIL has a well-known toxicity profile due to its effects on rapidly dividing cells:

• Hematological: Neutropenia, anemia, thrombocytopenia, increasing risks of infection, fatigue, and bleeding.
• Gastrointestinal: Nausea, vomiting, diarrhea, stomatitis, mucositis, and abdominal pain are common.
• Dermatological: Hand-foot syndrome (palmar-plantar erythrodysesthesia), rash, photosensitivity, and skin dryness.
• Cardiotoxicity: Rare but serious side effects include angina, arrhythmias, and myocardial ischemia.
• Neurological: Fatigue, headache, dizziness, and rarely cerebellar dysfunction or encephalopathy.
• Other: Alopecia, injection site reactions, fever, and malaise.

Side effects should be promptly reported and managed to prevent complications and allow continuation of therapy.

5-FLUOROURACIL "EBEWE" 500mg/10ml Contraindications 5-FLUOROURACIL "EBEWE" 500mg/10ml

Key contraindications include:

• Hypersensitivity: Known allergy to fluorouracil or any excipients in the formulation.
• Pregnancy and Lactation: Contraindicated due to potential teratogenicity and fetal harm.
• Severe Bone Marrow Suppression: Risks of severe, life-threatening hematologic toxicity.
• Active Severe Infection: Immunosuppressed patients are at heightened risk.
• Cardiac Disease: Severe heart conditions may be exacerbated by therapy.
• Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Such patients have a higher risk of severe toxicity and should avoid 5-FU.

A thorough medical evaluation is essential before starting treatment to identify any contraindications.

Storage of 5-FLUOROURACIL "EBEWE" 500mg/10ml

Proper storage of 5-FLUOROURACIL "EBEWE" is essential to maintain its stability and effectiveness:

• Store in the original glass vial, protected from light.
• Keep at controlled room temperature, usually between 15°C and 25°C (59°F to 77°F).
• Do not freeze or refrigerate the concentrate vial.
• Keep out of reach of children and unauthorized personnel.
• Once diluted for infusion, use within the time frame recommended by the manufacturer or hospital protocols, as the solution may degrade.
• Dispose of any unused or expired drug according to institutional guidelines for cytotoxic waste.

Following these storage guidelines ensures the medication remains safe and effective for patient use.